Efficacy and safety of oral MEK162 in patients with locally advanced and unresectable or metastatic cutaneous melanoma harboring BRAFV600 or NRAS mutations.
Paolo Antonio Ascierto
Consultant or Advisory Role - Amgen; Bristol-Myers Squibb; GlaxoSmithKline; Merck Sharp & Dohme; Roche/Genentech
Honoraria - Bristol-Myers Squibb; Merck Sharp & Dohme; Roche/Genentech
Carola Berking
Honoraria - Novartis
Sanjiv S Agarwala
Honoraria - Novartis
Dirk Schadendorf
No relevant relationships to disclose
Carla Van Herpen
No relevant relationships to disclose
Paola Queirolo
No relevant relationships to disclose
Christian U. Blank
Consultant or Advisory Role - Novartis
Research Funding - Novartis
Axel Hauschild
Consultant or Advisory Role - Novartis
Honoraria - Novartis
Research Funding - Novartis
J. Thaddeus Beck
Research Funding - Novartis
Angela Zubel
Employment or Leadership Position - Novartis
Stock Ownership - Novartis
Faiz Niazi
Employment or Leadership Position - Novartis
Simon Wandel
Employment or Leadership Position - Novartis
Reinhard Dummer
Consultant or Advisory Role - Novartis
Honoraria - Novartis
Research Funding - Novartis